
A fresh face has joined the board at the US-based biopharmaceutical company Syros Pharmaceuticals in the form of Deborah Dunsire, CEO at Lundbeck, a press release reveals.
"Syros has all the elements for building an enduring company – programs with the potential to set new standards of care for patients, a discovery engine to continue to fuel its pipeline, and great people," Dunsire says in the release, and adds:
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app